Pulmatrix's iSPERSE technology Treats Pulmonary Disorders
LEXINGTON, MA: Pulmatrix, a clinical biopharmaceutical company, has developed iSPERSE inhaled dry powder technology to treat lung diseases using dry powders. Certain salts and amino acids have been combined in such a way that they offer new ways of treating the lung diseases or probably transport the pharmaceuticals to the lungs for their effective functioning. These drugs are clinically validated regarding treating the serious pulmonary diseases.
Pulamtrix has received grants for patents from the U.S. Patent and Trademark Office. Robert W. Clarke, Ph.D., CEO of Pulmatrix says, "These issuances build upon previously issued international patents and reflect our aggressive strategy to broadly protect the global IP position of our core iSPERSE technology."
The products developed have remarkable traits of treating rare diseases such as, PUR1900 for cystic fibrosis (CF); PUR1500 for idiopathic pulmonary fibrosis; and PUR0200 for idiopathic pulmonary fibrosis. Pulmatrix’s accomplishment lies in their dry powder delivery platform, which enhances the therapeutic delivery to the lungs so as to improve the patient conditions. This approach has very less chances of causing side effects.
iSPERSE technology is flow rate independent, which provides reliable dosage delivery depending on the patient’s needs.The small, dense iSPERSE particles are easily dispersible on inhalation. It supplies the particles to the airways so that the drugs reach the lungs on time
"These patent grants further validate the novelty and relevance of the iSPERSE™ technology," statesDavid Hava, Ph.D., Chief Scientific Officer, Pulmatrix.